• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Repligen Reports First Quarter 2025 Financial Results

    4/29/25 7:30:00 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGEN alert in real time by email
    • Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growth
    • Orders increased sequentially and high-teens year-over-year
    • Adjusted operating income increased 72% year-over-year
    • Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5%

    WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025.

    Olivier Loeillot, President and Chief Executive Officer of Repligen said, "We had a strong start to the year with $169 million of revenue, which represented 14% organic non-COVID growth and helped drive meaningful adjusted operating margin expansion. Total orders grew nearly 20%, with all four franchises growing double-digits, highlighting the momentum in our business. As a result, we are confident in our organic growth outlook for the full year. Strategically, we strengthened our Analytics franchise with the acquisition of 908's bioprocessing portfolio. Finally, we are working to navigate through the current economic environment and at this point in time, we see minimal impact from tariffs on our EPS."

    Q1 2025 BUSINESS HIGHLIGHTS

    • Biopharma and consumables. Revenues for both biopharma and consumables increased greater than 20% year-over-year, reaching record levels excluding COVID.
    • M&A. Closed acquisition of 908 Devices' bioprocessing portfolio, complementing and strengthening our process analytical technology (PAT) offering with upstream capabilities.
    • New products. Launched CTech™ SoloVPE® Plus System, our next generation UV-based Variable Pathlength Technology system offering unparalleled accuracy, speed and ease-of-use.

    FINANCIAL PERFORMANCE

    Q1 2025 financial performance (compared to prior year periods except as noted).

    All adjusted figures are non-GAAP and, except for earnings per share, are rounded to the nearest million, and are reconciled in the tables included later in this press release.

    • Total reported revenue was $169 million compared to $153 million, an increase of 10% reported and 11% organic or 14% organic non-COVID.
    • GAAP gross profit was $91 million compared to $77 million. Adjusted gross profit was $91 million compared to $75 million.
    • GAAP income from operations was $7 million, compared to $4 million. Adjusted income from operations was $23 million, compared to $14 million.
    • GAAP net income (GAAP) was $6 million, compared to $3 million. Adjusted net income was $22 million compared to $17 million.
    • GAAP earnings per share was $0.10 on a fully diluted basis, compared to $0.06. Adjusted earnings per share was $0.39 on a fully diluted basis, compared to $0.30.

    MARGIN SUMMARY

    GAAP Margins Q1 2025 Q1 2024
    Gross Margin 53.6% 50.1%
    Operating (EBIT) Margin 3.9% 2.4%
         
    Adjusted (non-GAAP) Margins Q1 2025 Q1 2024
    Gross Margin 53.7% 49.2%
    Operating (EBIT) Margin 13.8% 8.9%
    EBITDA Margin 19.3% 14.4%
         

    Cash and cash equivalents at March 31, 2025, were $697 million, compared to $757 million at December 31, 2024.

    FINANCIAL GUIDANCE FOR FISCAL YEAR 2025

    Our financial guidance for the fiscal year 2025 is based on expectations for our existing business. Our GAAP and Adjusted (non-GAAP) guidance excludes the impact of any potential business acquisitions in 2025, tariffs, and future fluctuations in foreign currency exchange rates.

      CURRENT GUIDANCE
      (at April 29, 2025)
    FY 2025 GAAP  Adjusted (non-GAAP)
    Total Reported Revenue $695M - $720M  $695M - $720M
    Reported Growth 9.5% - 13.5%  9.5% - 13.5%
    Organic Growth —  9.5% - 13.5%
    Organic, Non-COVID Growth —  11.5% - 15.5%
    Gross Margin 52% - 53%  52% - 53%
    Income from Operations $48M - $55M  $95M - $102M
    Operating Margin 7% - 8%  13.5% - 14.5%
    Other Income (Expense) $7M - $8M  $23M - $24M
    Adjusted EBITDA Margin —  19.5% - 20.5%
    Tax Rate on Pre-Tax Income 23% - 24%  22% - 23%
    Net Income $43M - $48M  $92M - $97M
    Earnings Per Share - Diluted $0.76 - $0.85  $1.63 - $1.72
          

    Updated guidance incorporates the impact of the acquisition of 908 Devices' Bioprocessing Analytics business including: a revenue increase of $10 million, a $4 million reduction in income from operations and the associated impact on operating margin, adjusted EBITDA margin, net income and earnings per share, diluted. Additionally, there is a 100-basis point increase in gross margin versus our prior guidance. This primarily relates to a shift in costs to operating expenses from cost of goods sold, where they previously were assumed in our prior guidance. There is no impact on operating income associated with this change. 

    Conference Call and Webcast Access

    Repligen will host a conference call and webcast today, April 29, 2025, at 8:30 a.m. ET, to discuss first quarter 2025 financial results, corporate developments and financial guidance for the year 2025. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers or (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 6386085.

    About Repligen Corporation

    Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are "inspiring advances in bioprocessing" for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.

    Non-GAAP Measures of Financial Performance

    To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following Adjusted (non-GAAP) measures of financial performance are included in this release: organic non-COVID revenue and non-COVID revenue growth; organic revenue and organic revenue growth; adjusted cost of goods sold, adjusted gross profit and adjusted gross margin; adjusted R&D expense and adjusted SG&A expense; adjusted income from operations and adjusted operating margin; adjusted pre-tax income; adjusted net income; adjusted earnings per share (diluted); adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA margin. The Company provides the impact of foreign currency translation, to enable determination of revenue growth rates at constant currency. To calculate the impact of foreign currency translation, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior year periods.

    The Company's non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition and integration costs; restructuring charges including the costs of severance and accelerated depreciation among other charges; incremental costs attributed to CEO transition; contingent consideration related to the Company's acquisitions; intangible amortization costs; non-cash interest expense related to the accretion of the debt discount; amortization of debt issuance costs related to Company's convertible debt; foreign currency impact of certain intercompany loans; and, the related impact on tax of non-GAAP charges. These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

    NOTE:

    All reconciliations of above GAAP figures (reported or guidance) to adjusted (non-GAAP) figures are detailed in the tables included later in this press release. When analyzing the Company's operating performance and guidance, investors should not consider non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.

    Forward-Looking Statements

    This press release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein which do not describe historical facts, including, among others, any express or implied statements or guidance regarding current or future financial performance and position, including our 2025 financial guidance and related assumptions; expected demand in the markets in which we operate; expectations regarding the acquisition of 908 Devices' bioprocessing portfolio; and the expected performance of our business and momentum across our portfolio, are based on management's current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

    Such risks and uncertainties include, among others, our ability to successfully grow our bioprocessing business; our ability to manage through and predict headwinds; the risk that we have assumed that markets and franchises will improve and grow more than expected; our ability to achieve our 2025 financial guidance; our ability to develop and commercialize products and the market acceptance of our products; our ability to successfully integrate any acquired businesses and relevant personnel in a timely manner or at all, and to achieve the expected benefits of such acquisitions; that demand for our products could decline, which could adversely impact our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing companies; risks around the Company's effectiveness of disclosure controls and procedures and the effectiveness of our internal control over financial reporting; our compliance with all U.S. Food and Drug Administration and European Medicines Evaluation Agency regulations; our volatile stock price; the impact of tariffs on our business, and other risks and uncertainties detailed in Repligen's filings with the U.S. Securities and Exchange Commission (the Commission), including our Annual Report on Form 10-K for the year ended December 31, 2024 and in subsequently filed reports with the Commission, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and any subsequent filings made with the Commission, which are available at the Commission's website at www.sec.gov. Actual results may differ materially from those Repligen contemplated by these forward-looking statements, which reflect management's current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Repligen disclaims any obligation to update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. 

    Repligen Contact:

    Jacob Johnson

    VP, Investor Relations

    (781) 419-0204

    [email protected]



    REPLIGEN CORPORATION

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (Unaudited, amounts in thousands, except share and per share data)

      Three Months Ended

    March 31,
     
      2025  2024 
    Revenue:      
    Product revenue $169,137  $153,146 
    Royalty and other revenue  35   36 
    Total revenue  169,172   153,182 
    Costs and expenses:      
    Cost of goods sold  78,415   76,391 
    Research and development  12,924   11,238 
    Selling, general and administrative  71,255   61,803 
       162,594   149,432 
    Income from operations  6,578   3,750 
    Investment income  7,314   8,993 
    Interest expense  (5,250)  (5,029)
    Amortization of debt issuance costs  (413)  (483)
    Other income (expenses), net  (286)  (3,536)
    Income before income taxes  7,943   3,695 
    Income tax provision  2,113   399 
    Net income $5,830  $3,296 
    Earnings per share:      
    Basic $0.10  $0.06 
    Diluted $0.10  $0.06 
    Weighted average shares outstanding:      
    Basic  56,122,742   55,791,289 
    Diluted  56,558,072   56,531,476 



    Balance Sheet Data: March 31,

    2025
      December 31,

    2024
     
    Cash and cash equivalents $697,229  $757,355 
    Working capital  880,469   939,254 
    Total assets  2,852,143   2,829,666 
    Long-term obligations  714,664   730,161 
    Accumulated earnings  413,184   407,354 
    Stockholders' equity  1,985,483   1,972,718 
             

    REPLIGEN CORPORATION

    RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES

    (Unaudited, amounts in thousands, except percentage and earnings per share data)

    In all tables below, totals may not add due to rounding

    Reconciliation of Total Revenue (GAAP) Growth to Organic Non-COVID Revenue Growth (Non-GAAP)

      Three Months Ended

    March 31,
     
      2025  2024 
    TOTAL REPORTED REVENUE (GAAP) GROWTH  10%  (7)%
    Acquisition revenue  (1)%  (4)%
    Currency exchange  1%  1%
    ORGANIC REVENUE GROWTH (NON-GAAP)  11%  (11)%
    COVID revenue  2%  1%
    ORGANIC NON-COVID REVENUE GROWTH (NON-GAAP)  14%  (10)%
     

    Reconciliation of Income from Operations (GAAP) to Adjusted Income from Operations (Non-GAAP)

      Three Months Ended

    March 31,
     
      2025  2024 
    INCOME FROM OPERATIONS (GAAP) $6,578  $3,750 
    ADJUSTMENTS TO INCOME FROM OPERATIONS (GAAP):      
    Acquisition and integration costs  6,033   1,755 
    Restructuring activities and other related charges(1)  1,089   (584)
    Intangible amortization  9,121   8,716 
    Other(2)  584   — 
    ADJUSTED INCOME FROM OPERATIONS (NON-GAAP) $23,405  $13,637 
    OPERATING (EBIT) MARGIN  3.9%  2.4%
    ADJUSTED OPERATING (EBIT) MARGIN  13.8%  8.9%
             

    Reconciliation of Net Income (GAAP) to Adjusted Net Income (Non-GAAP)

      Three Months Ended

    March 31,
     
      2025  2024 
    NET INCOME (GAAP) $5,830  $3,296 
    ADJUSTMENTS TO NET INCOME (GAAP):      
    Acquisition and integration costs  6,033   1,755 
    Restructuring activities and other related charges(1)  1,089   (584)
    Intangible amortization  9,121   8,716 
    Non-cash interest expense  3,747   3,464 
    Amortization of debt issuance costs  413   483 
    Foreign currency impact of certain intercompany loans (3)  —   3,787 
    Other(2)  584   — 
    Tax effect of non-GAAP charges  (4,576)  (3,690)
    ADJUSTED NET INCOME (NON-GAAP) $22,241  $17,227 
     

    Reconciliation of Earnings Per Share (GAAP) to Adjusted Earnings Per Share (Non-GAAP)

      Three Months Ended

    March 31,
     
      2025  2024 
    EARNINGS PER SHARE (GAAP) - DILUTED $0.10  $0.06 
    ADJUSTMENTS TO EARNINGS PER SHARE (GAAP) - DILUTED:      
    Acquisition and integration costs  0.11   0.03 
    Restructuring activities and other related charges(1)  0.02   (0.01)
    Intangible amortization  0.16   0.15 
    Non-cash interest expense  0.07   0.06 
    Amortization of debt issuance costs  0.01   0.01 
    Foreign currency impact of certain intercompany loans (3)  —   0.07 
    Other(2)  0.01   — 
    Tax effect of non-GAAP charges  (0.08)  (0.07)
    ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED $0.39  $0.30 
     

    Reconciliation of Net Income (GAAP) to Adjusted EBITDA (Non-GAAP)

      Three Months Ended

    March 31,
     
      2025  2024 
    NET INCOME (GAAP) $5,830  $3,296 
    ADJUSTMENTS:      
    Investment income  (7,314)  (8,993)
    Interest expense  5,250   5,029 
    Amortization of debt issuance costs  413   483 
    Income tax provision  2,113   399 
    Depreciation  9,555   8,145 
    Intangible amortization(4)  9,149   8,744 
    EBITDA (NON-GAAP)  24,996   17,103 
    OTHER ADJUSTMENTS:      
    Acquisition and integration costs  6,033   1,755 
    Restructuring activities and other related charges (1)(5)  1,089   (584)
    Foreign currency impact of certain intercompany loans (3)  —   3,787 
    Other(2)  584   — 
    ADJUSTED EBITDA (NON-GAAP) $32,702  $22,061 
    ADJUSTED EBITDA MARGIN (NON-GAAP)  19.3%  14.4%
     

    Reconciliation of Cost of Goods Sold (GAAP) to Adjusted Cost Goods Sold (Non-GAAP)

      Three Months Ended

    March 31,
     
      2025  2024 
    COST OF GOODS SOLD (GAAP) $78,415  $76,391 
    ADJUSTMENT TO COST OF GOODS SOLD (GAAP):      
    Acquisition and integration costs  (103)  (66)
    Restructuring activities and other related charges(1)  270   1,448 
    Intangible amortization  (187)  — 
    ADJUSTED COST OF GOODS SOLD (NON-GAAP) $78,395  $77,773 
    GROSS MARGIN (GAAP)  53.6%  50.1%
    ADJUSTED GROSS MARGIN (NON-GAAP)  53.7%  49.2%
             

    Reconciliation of R&D Expense (GAAP) to Adjusted R&D Expense (Non-GAAP)

      Three Months Ended

    March 31,
     
      2025  2024 
    R&D EXPENSE (GAAP) $12,924  $11,238 
    ADJUSTMENT TO R&D EXPENSE (GAAP):      
    Acquisition and integration costs  (420)  (53)
    Restructuring activities and other related charges(1)  (810)  (165)
    Intangible amortization  (357)  — 
    ADJUSTED R&D EXPENSE (NON-GAAP) $11,337  $11,020 
     

    Reconciliation of SG&A Expense (GAAP) to Adjusted SG&A Expense (Non-GAAP)

      Three Months Ended

    March 31,
     
      2025  2024 
    SG&A EXPENSE (GAAP) $71,255  $61,803 
    ADJUSTMENTS TO SG&A EXPENSE (GAAP):      
    Acquisition and integration costs  (5,510)  (1,636)
    Restructuring activities and other related charges(1)  (549)  (699)
    Intangible amortization  (8,577)  (8,716)
    Other(2)  (584)  — 
    ADJUSTED SG&A EXPENSE (NON-GAAP) $56,035  $50,752 
     

    Reconciliation of Net (Loss) Income (GAAP) Guidance to Adjusted Net Income (Non-GAAP) Guidance

      Year Ending December 31, 2025 
      Low End  High End 
    GUIDANCE ON NET INCOME (GAAP) $43,000  $48,000 
    ADJUSTMENTS TO GUIDANCE ON NET INCOME (GAAP):      
    Acquisition and integration costs  11,505   11,505 
    Restructuring activities and other related charges(1)  1,464   1,464 
    Anticipated pre-tax amortization of acquisition-related intangible assets  33,384   33,384 
    Non-cash interest expense  14,586   14,586 
    Amortization of debt issuance costs  1,646   1,646 
    Tax effect of non-GAAP charges  (13,699)  (13,699)
    Other(2)  584   584 
    Guidance rounding adjustment  (470)  (470)
    GUIDANCE ON ADJUSTED NET INCOME (NON-GAAP) $92,000  $97,000 
     

    Reconciliation of Earnings Per Share (GAAP) Guidance to Adjusted Earnings Per Share (Non-GAAP) Guidance

      Year Ending December 31, 2025 
      Low End  High End 
    GUIDANCE ON EARNINGS PER SHARE (GAAP) - DILUTED $0.76  $0.85 
    ADJUSTMENTS TO GUIDANCE ON EARNINGS PER SHARE (GAAP) - DILUTED:      
    Acquisition and integration costs  0.20   0.20 
    Restructuring activities and other related charges(1)  0.03   0.03 
    Anticipated pre-tax amortization of acquisition-related intangible assets  0.59   0.59 
    Non-cash interest expense  0.26   0.26 
    Amortization of debt issuance costs  0.03   0.03 
    Tax effect of non-GAAP charges  (0.24)  (0.24)
    Other(2)  0.01   0.01 
    Guidance rounding adjustment  (0.01)  (0.01)
    GUIDANCE ON ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED $1.63  $1.72 
     

    FOOTNOTES FOR ALL TABLES ABOVE (amounts in thousands):

    (1)    In July 2023, we began restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations. The Company continued further restructuring activities during the three months ended March 31, 2025 including severance, employee-related and facility exit costs. Cost of goods sold includes the benefit received from the sale of inventory that had previously been reserved as part of the restructuring plan of $885 and $2,007 for the three months ended March 31, 2025 and 2024, respectively.

    (2)    Includes one-time events relating to a cybersecurity incident, net of insurance, and costs associated with the restatement of previously issued financial statements.    

    (3)    During the first quarter of 2024 we recorded foreign currency losses on certain intercompany loans of $3,787. The impact was recorded to the Other expenses, net line item within the Condensed Consolidated Statements of Operations.

    (4)    Includes amortization of milestone payments in accordance with GAAP of $28 for the three months ended March 31, 2025 and 2024.

    (5)    Excludes $19 of accelerated depreciation related to the restructuring plan for the three months ended March 31, 2024. This amount is included in the depreciation line item of this table.



    Primary Logo

    Get the next $RGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RGEN

    DatePrice TargetRatingAnalyst
    4/29/2025$160.00Peer Perform → Outperform
    Wolfe Research
    3/18/2025$155.00In-line
    Evercore ISI
    2/10/2025$200.00Buy
    TD Cowen
    12/17/2024$165.00Hold
    Canaccord Genuity
    11/14/2024Peer Perform
    Wolfe Research
    8/28/2024$180.00Overweight
    Wells Fargo
    6/26/2024$180.00 → $155.00Hold → Buy
    Deutsche Bank
    6/18/2024Neutral
    Guggenheim
    More analyst ratings

    $RGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pax Margaret bought $37,672 worth of shares (250 units at $150.69), increasing direct ownership by 32% to 1,043 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      3/18/25 3:58:05 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Madaus Martin D bought $201,776 worth of shares (1,615 units at $124.94) (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      6/14/24 6:07:59 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Barthelemy Nicolas bought $150,540 worth of shares (1,200 units at $125.45), increasing direct ownership by 35% to 4,668 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      6/14/24 5:42:58 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Repligen Corporation to Present at William Blair Growth Conference

      WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen CorporationRepligen Corporation is a global

      5/22/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen Corporation to Present at Upcoming May Investor Conferences

      WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets' 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-one meetings with investors.Craig-Hallum's 22nd Annual Institutional Investor Conference, being held in Minneapolis on May 28. Jason K. Garland, Chief Financial Officer will participate in a series

      5/7/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen Reports First Quarter 2025 Financial Results

      Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer

      4/29/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Repligen upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Repligen from Peer Perform to Outperform and set a new price target of $160.00

      4/29/25 2:20:14 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Repligen with a new price target

      Evercore ISI initiated coverage of Repligen with a rating of In-line and set a new price target of $155.00

      3/18/25 7:55:20 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on Repligen with a new price target

      TD Cowen initiated coverage of Repligen with a rating of Buy and set a new price target of $200.00

      2/10/25 7:05:45 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Repligen Appoints Jacob Johnson As Vice President Investor Relations

      WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the company's Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garland commented, "Jacob is a terrific addition to the Repligen team, bringing a broad understanding of the bioprocessing tools space, the markets we serve and the growth driver

      4/8/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

      BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

      12/16/24 8:11:00 AM ET
      $BLFS
      $RGEN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Repligen Announces CEO Transition Plan

      WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors ("Board") has approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of

      6/13/24 7:00:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    SEC Filings

    See more
    • Repligen Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - REPLIGEN CORP (0000730272) (Filer)

      5/15/25 4:15:37 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Repligen Corporation

      10-Q - REPLIGEN CORP (0000730272) (Filer)

      4/29/25 4:17:25 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - REPLIGEN CORP (0000730272) (Filer)

      4/29/25 7:32:59 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Repligen Corporation

      SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

      11/14/24 1:22:37 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Repligen Corporation

      SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

      9/10/24 5:08:30 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

      SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

      2/14/24 10:02:59 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Barthelemy Nicolas was granted 973 shares, increasing direct ownership by 28% to 4,441 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      5/21/25 3:00:13 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Konstantinov Konstantin was granted 973 shares, increasing direct ownership by 51% to 2,894 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      5/19/25 8:26:29 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Muir Glenn P was granted 973 shares, increasing direct ownership by 3% to 33,256 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      5/19/25 8:19:08 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Financials

    Live finance-specific insights

    See more
    • Repligen Reports First Quarter 2025 Financial Results

      Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer

      4/29/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen to Report First Quarter 2025 Financial Results

      WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2025. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company

      4/15/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

      WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen's differentiated PAT portfolio that provides its bioph

      3/4/25 7:30:00 AM ET
      $MASS
      $RGEN
      Industrial Machinery/Components
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care